Outlook Therapeutics, Inc. (OTLK): Shareholders' Equity
-$32.19M
As of 2025-09-30
-$10.39M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | -$32.19M | n/m | 2025-12-19, Balance as of period end |
| 2024-09-30 | -$73.08M | n/m | 2025-12-19, Balance as of period end |
| 2023-09-30 | -$14.44M | n/m | 2024-12-27, Balance as of period end |
| 2022-09-30 | $8.74M | +89.6% | 2023-12-22, Balance as of period end |
| 2021-09-30 | $4.61M | +63.0% | 2022-12-29, Balance as of period end |
| 2020-09-30 | $2.83M | n/m | 2021-12-23, Balance as of period end |
| 2019-09-30 | -$16.13M | n/m | 2020-12-23, Balance as of period end |
| 2018-09-30 | -$25.54M | n/m | 2019-12-19, Balance as of period end |
| 2017-09-30 | -$33.65M | n/m | 2018-12-18, Balance as of period end |
| 2016-09-30 | -$5.17M | n/m | 2017-12-29, Balance as of period end |
| 2015-09-30 | -$54.22M | n/a | 2016-12-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | -$32.19M | n/m |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $8.10M | -18.8% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $7.99M | -94.0% |
| Pluri Inc. (PLUR) | 2026-06-30 | -$23.04M | n/m |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $3.11M | n/m |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $53.55M | n/m |
| Prokidney Corp. (PROK) | 2025-12-31 | -$1.01B | n/m |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $133.14M | n/m |
| Dyadic International Inc (DYAI) | 2025-12-31 | $1.23M | -50.1% |
Compare OTLK, SCNI, INBX, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗